NIM Norwood Imm.

RNS Number:8442C
Norwood Immunology Ld
12 May 2006


For immediate release                                                12 May 2006




                           NORWOOD IMMUNOLOGY LIMITED
                    ('Norwood Immunology' or 'the Company')



VIROSOME BIOLOGICALS SUCCESSFULLY COMPLETES PHASE I FLU TRIAL AND MOVES TO PHASE
                                       II


                        - milestone payment triggered -


Norwood Immunology Limited (AIM: NIM), the company focussed on the rejuvenation
of the immune system, today announces important progress in the clinical trial
programme of Virosome Biologicals Limited ("Virosome Biologicals"), the company
over which NIM has an option to acquire 100% of its share capital.

Virosome Biologicals' adjuvanted virosome technology is licensed to Solvay
Pharmaceuticals in the field of intranasal influenza vaccines. Solvay is
responsible for clinical trials and development and commercialising of the
vaccine.

Norwood Immunology is pleased to report that Solvay Pharmaceuticals has now
successfully concluded a Phase I clinical trial with the intranasal influenza
vaccine, triggering a milestone payment to Virosome Biologicals. The vaccine was
found to be safe and well tolerated.  Solvay Pharmaceuticals will continue to
test the vaccine in Phase II clinical trials.

Richard Williams, CEO of Norwood Immunology, commented: "Progress into Phase II
is an important milestone for Virosome Biologicals and an endorsement of its
technology in intranasal flu vaccines by its partner, Solvay Pharmaceuticals.
This news is extremely encouraging and we will continue to work closely with
Virosome Biologicals throughout the option period on this clinical trial
programme and, indeed, on the broader licensing opportunities for their core
technologies"


For further information please contact:

Richard Williams, Chief Executive Officer, Norwood Immunology Limited
+44 (0) 7860 295153

Lisa Baderoon, Mark Court, Mary-Jane Johnson, Buchanan Communications
+44 (0) 207 466 5000


Notes for editors:

About virosomes and Virosome Biologicals

Virosomes are reconstituted virus membranes, in this case influenza (flu)
containing the viral membrane protein, hemagglutinin. This protein induces
membrane fusion, activating a strong immune response against antigens contained
within the virosomes. Thus, virosomes are ideal vaccines not only for the
influenza virus itself, but also as carriers for vaccines against other viral
diseases and cancer. Virosomes do not contain the genetic material of influenza
virus, and therefore are not infectious.

Virosome Biologicals is developing and commercialising a proprietary platform
enabling technology for vaccines. The technology - which is based upon the
combination of an adjuvant with virosomes - achieves a significantly enhanced
immune response to an antigen challenge. The adjuvant specifically interacts
with Toll-like Receptors (TLRs).

About Solvay Pharmaceuticals

SOLVAY PHARMACEUTICALS is a research driven group of companies that constitute
the global pharmaceutical business of SOLVAY Group. The company seeks to fulfill
carefully selected, unmet medical needs in the therapeutic areas of
neuroscience, cardio-metabolic, influenza vaccines, pancreatic enzymes,
gastroenterology and men's and women's health. Its 2005 sales were EUR 2,3
billion. SOLVAY is an international chemicals and pharmaceuticals group with
headquarters in Brussels. Details are available at www.solvay.com.




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
MSCILFIREFILLIR

Grafico Azioni Norwood Immunology (LSE:NIM)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Norwood Immunology (LSE:NIM)
Storico
Da Giu 2023 a Giu 2024